GLUT4はキューしている? 脂肪細胞におけるインスリン反応のメカニズム的数学モデル
Brock D Sherlock1,2, Marko A A Boon2, Maria Vlasiou3
1School of Mathematics & Statistics, University of New South Wales, Sydney, 2052, NSW, Australia.
Bulletin of mathematical biology
|September 2, 2025
まとめ
哺乳類の細胞はグルコーストランスポーター4 (GLUT4) を用いて血糖を制御する. インスリンがGLUT4を細胞表面に移動させ,融合部位の活性が,この重要なグルコース輸送プロセスを制御する可能性がある.
科学分野:
- 細胞生物学
- バイオ物理学
- 代謝の調節
背景:
- 哺乳類の細胞は,細胞内グルコーストランスポータータンパク質の再配分によってグルコースホメオスタシスを調節する.
- グルコーストランスポーター4 (GLUT4) はインスリンが制御する主要なトランスポーターで,インスリン信号によって細胞内貯蔵物から細胞表面に移動する.
- GLUT4の放出とプラズマ膜輸送を制御する正確なメカニズムは,まだ完全に理解されていません.
研究 の 目的:
- グルコーストランスポーター4 (GLUT4) 転位の生物学的に妥当なモデルを提示する.
- GLUT4の動態を調節する核融合場所の可用性の役割を調査する.
- 細胞表面へのGLUT4輸送の主な決定因子を明らかにする.
主な方法:
- ストキャスティックキューモデルの開発
- GLUT4ベシクルダイナミクスシミュレーション
- インスリン濃度の関数として融合部位の活性分析.
主要な成果:
- このモデルは,GLUT4を含有する泡の融合部位の数を変化させることで,実験的観測を説明できることを示しています.
- 結合部位の可用性のインスリン依存的調節は,観察されたGLUT4再分配ダイナミクスを再現するのに十分である.
- 融合部位の活動は,GLUT4の転位率を制御する重要な要因として浮上しています.
結論:
- 核融合部位の数と活動は,GLUT4転移の重要な調節因子である.
- 提案されたモデルは,インスリン刺激によるGLUT4トラフィックのメカニズム的説明を提供します.
- この研究は,細胞のグルコース吸収調節の潜在的な主要な決定因子として,融合部位のダイナミクスを強調しています.
さらに関連する動画
関連する概念動画
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Insulin Secretory Vesicles
5.4K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Insulin: Biosynthesis, Chemistry, and Preparation
518
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
518
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253


